Search Results for "Retrovir"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Retrovir. Results 1 to 2 of 2 total matches.
See also: zidovudine
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
. The T cells are sent to a commercial
laboratory, which genetically modifies them via
retroviral transduction ...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 doi:10.58347/tml.2023.1678f | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
roxaparvovec. The anti-retroviral
drug efavirenz can suppress factor VIII transcription;
concurrent use ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction